drugset / Trial / NCT03829696
Advance Provision of Medication Abortion
NaSingle-groupOpen-labelHealth-services research
Summary
This mixed-methods study follows a prospective cohort of participants receiving Mifeprex® (mifepristone) by a clinician in advance of a potential unintended pregnancy. Women participating in this study will be assessed by a clinician and provided Mifeprex® and misoprostol in a clinical setting. To assess acceptability of this service delivery model among participants, and feasibility of implementing a larger randomized controlled trial, the study will survey participants, evaluate any clinical outcomes recorded during clinical visits, and interview participants about their experiences participating in the study.
Timeline
- Start
- 2020-01
- Primary completion
- 2021-01
- Completion
- 2021-01
Publications
- Background FDA (2016).
- Background Biggs MA, Ralph L, Raifman S, Foster DG, Grossman D. Support for and interest in alternative models of medication abortion provision among a national probability sample of U.S. women. Contraception. 2019 Feb;99(2):118-124. doi: 10.1016/j.contraception.2018.10.007. Epub 2018 Nov 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mifepristone | Small molecule | 200 mg | Oral |
| Subject | Misoprostol | Other / unclassified | 800 ug | Other |
| Background | Ulipristal Acetate | Unknown | 30 mg | — |
Indications
No indication recorded.